Registration of amiloride in South Africa: Cutting the Gordian knot by Rayner, B L et al.
632       September 2019, Vol. 109, No. 9
IN PRACTICE
Cutting the Gordian knot is a commonly used metaphor for solving 
an intractable problem that is resolved easily by a radically different 
approach. The legend dates to 333 BC when Alexander the Great 
marched into the city of Gordium in modern-day Turkey. On 
arriving, he encountered a wagon with its yoke tied in a knot, which 
no one could unfasten. After wrestling with the knot for some time, 
Alexander drew his sword and sliced the knot in half, so releasing the 
wagon from the yoke.
South Africa (SA) (and Africa) faces a similar problem in relation 
to the registration of amiloride for treatment of resistant or severe 
hypertension in the black African and mixed ancestry populations; 
there needs to be a radical new approach to address this pressing 
issue.
Amiloride is a potassium-sparing diuretic that blocks the epithelial 
sodium channel (ENaC) in the collecting duct of the kidney, resulting 
in natriuresis and retention of potassium and magnesium.[1] The 
ENaC is the final regulator of sodium balance in the kidney and 
therefore plays a crucial role in sodium regulation and blood pressure 
(BP) control.[2] The main indication for amiloride is for the treatment 
of hypertension; it is listed as a World Health Organization (WHO) 
essential drug.[3] Although developed >50 years ago, amiloride did 
not gain widespread use in the treatment of hypertension and is 
hardly mentioned in most hypertension guidelines. 
Amiloride alone has never been registered in SA, but is available in a 
combination tablet with hydrochlorothiazide (HCTZ) (amiloride 5 mg, 
HCTZ 50 mg). Although this combination tablet may lower blood 
pressure, there are two problems: (i) the dose of HCTZ is too high, 
with a propensity for electrolyte abnormalities at full dose that can 
be severe and life threatening;[1] and (ii) if half the dose is used to 
minimise electrolyte abnormalities, the dose of amiloride (2.5 mg) 
is insufficient to adequately target the ENaC. As pure amiloride has 
never been registered, it can only be prescribed on a case-by-case 
basis, approved by the SA Health Products Regulatory Authority 
(SAHPRA) under a Section 21 application.
Targeting the ENaC is critically important in black Africans to control 
severe or resistant hypertension. Given the number of patients affected, 
this is not feasible when approval of the drug is required on a case-by-
case basis. The reasons for targeting the ENaC in black hypertensive 
patients are a tale of two research groups working independently on 
two different continents, coming to the same conclusion, and then 
collaborating to perform a clinical trial that confirmed this approach. 
The tale of amiloride
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Amiloride is an antagonist of the renal tubular epithelial sodium channel (ENaC). As such, it is a diuretic that is both potassium and 
magnesium sparing. It is used for the treatment of potassium depletion and hypertension, and is the specific therapy for hypertension 
due to overactivity of the ENaC (Liddle syndrome and several additional genetic causes of the Liddle phenotype – low renin and low 
aldosterone). It is listed as a World Health Organization essential drug, but has never been registered in South Africa (SA) and can therefore 
only be prescribed under a Section 21 application to the SA Health Products Regulatory Authority (SAHPRA) on a case-by-case basis. In 
SA, >50% of patients treated for hypertension are not controlled. In the USA, the Reasons for Geographic and Racial Differences in Stroke 
(REGARDS) study reported that African Americans are more likely to be diagnosed with hypertension, more likely to be treated, more 
likely to be treated intensively, and less likely to achieve blood pressure (BP) control. Although the reasons are complex, studies show that 
10 - 20% of blacks may carry the Liddle phenotype. Observational data and a controlled clinical trial done in three African countries have 
shown that these patients respond to amiloride and not to conventional guideline-based antihypertensive treatment. The former is likely to 
result in a significant reduction in cardiovascular, stroke and kidney morbidity and mortality, because of improved BP control. Amiloride is 
very unlikely to ever be registered in SA, as it was first developed >50 years ago, and SAHPRA regulations prevent widespread prescription 
of this essential drug. This is a classic Gordian knot that requires a novel approach from authorities to sever the knot and improve the health 
of many South Africans. 
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Schuur Hospital, Cape Town, SA, in 1994. He was struck by the 
number of patients with severe drug-resistant hypertension, despite 
good medication adherence. Based on the work of Richard Gordon 
from Brisbane, Australia, who found that the prevalence of primary 
aldosteronism (PA) in their locality was 12%,[4] the aldosterone-
renin ratio to screen patients with drug-resistant hypertension was 
implemented by him. Thirty-two percent of patients had evidence 
suggestive of primary aldosteronism, and the introduction of 
spironolactone made a dramatic difference to BP control in these 
patients.[5]
Furthermore, during a screening programme to establish normal 
ranges of aldosterone and renin in three SA population groups (white, 
mixed ancestry and black), the mean plasma renin activity (PRA) and 
plasma aldosterone levels were significantly lower in black and mixed 
ancestry patients than in white patients, despite similar salt intake.[6] Low 
PRA and plasma aldosterone levels are the hallmark of the Liddle 
syndrome, which is an inherited condition due to mutations in the 
beta chain of the ENaC.[7] This results in excess expression of ENaC 
on the tubular cells of the collecting duct, resulting in increased 
sodium reabsorbtion despite suppressed aldosterone. The ENaC is a 
crucial site of salt balance and hence of BP control, as it is the final 
regulator of sodium balance in the kidney.[2] 
Consequently, the entire gene for the sodium channel epithelial 
beta (SCNN1β) subunit of the ENaC was sequenced and a novel 
single nucleotide polymorphism (SNP) (p.Arg563Gln or R563Q) 
was identified.[8] It was later shown to be associated with low renin- 
and low aldosterone-related hypertension in indigenous southern 
African and Cape mixed ancestry population groups;[8] there was a 
strong association with hypertension and the p.Arg563Gln mutation 
in blacks living in urban areas, and 5% of hypertensives were carriers.[9] 
In a kindred study, the p.Arg563Gln mutation strongly associated 
with hypertension,[10] and patients with severe hypertension carrying 
this mutation responded exceptionally well to amiloride, a specific 
inhibitor of ENaC.[9] The prevalence of the p.Arg563Gln mutation 
was 20% in the Khoi-San population, who are hunter-gatherer 
people living in the Kalahari desert, suggesting that this was the 
population of origin (for this variant) and may have offered survival 
advantage in a sodium-restricted environment.[9] In addition to 
true Liddle syndrome due to variants of ENaC, there are variants 
of at least 5 other genes that increase the activity of ENaC, resulting 
in a Liddle phenotype (GRK, NEDD4L, CYP4A11, NPPA, UMOD 
and perhaps others).[11] Therefore, although the prevalence of true 
Liddle syndrome may be only ~6% among resistant hypertensives 
in Cape Town, the prevalence of a Liddle phenotype, also selectively 
responsive to amiloride, is apparently much higher, as discussed 
below. 
London, Canada
The second author (JDS) is a neurologist and clinical pharmacologist 
in London, Ontario, Canada, with a special interest in hypertension 
and stroke prevention. He examined patients from an African 
American community in Buxton, near London, who were descendants 
of slaves who had escaped to Canada in the 1800s. Blacks were 
much more likely to have a low plasma renin, which at the time 
was attributed to primary aldosteronism, mostly due to bilateral 
adrenocortical hyperplasia (plasma aldosterone levels were then not 
available; therefore, the Liddle phenotype was unrecognised in that 
clinic population).[12]
In 2006, Spence[13] suggested that physiologically individualised 
therapy based on phenotyping with plasma renin and aldosterone 
had the potential to eliminate or at least markedly diminish the 
racial disparities in hypertension and stroke in the USA. A treatment 
algorithm was developed (Table 1), which resulted in excellent 
control rates for hypertension and a marked reduction in stroke.[14]
Physiologically individualised therapy in Africa
A randomised clinical trial was implemented to test this hypothesis 
in Africa, and evidence supporting this approach is available in 
hypertension clinics in Nigeria, Kenya and SA.[15] Patients whose BP 
was not controlled to <140 systolic mmHg or 90 diastolic mmHg 
were allocated to usual care (UC) v. physiologically individualised 
therapy (PhysRx). 
In the overall study, control of both systolic and diastolic BP was 
obtained in 11.1% of UC-treated patients v. 50.0% of PhysRx-treated 
patients (p<0.0001). Systolic control was achieved in 13.9% of UC 
patients v. 60.3% of PhysRx patients (p<0.0001); and diastolic control 
was achieved in 36.1% of UC patients v. 67.2% of PhysRx patients 
(p=0.003). At the Nigerian site, where patients were randomised and 
conditions were more similar to those in North America, systolic 
control was obtained in 15% of UC patients v. 85% of PhysRx patients 
(p=0.0001); diastolic control in 45% of UC patients v. 75% of PhysRx 
patients (p=0.11); and control of both systolic and diastolic pressure 
in 15% of UC patients v. 75% of PhysRx patients (p<0.0001), even 
though the renal function was worse at that site. The major difference 
in medication change during the study was with amiloride; at the end 
of the study amiloride was being taken by 19% of PhysRx patients v. 
only 2.8% of UC patients (p=0.02). This indicates that 19% of these 
patients with resistant hypertension had a Liddle phenotype.
Furthermore, in this study, genetic analysis of candidate genes was 
undertaken in those with the Liddle phenotype. Most patients had 
variants of several different genes affecting ENaC function. Among 
those with a primary aldosteronism phenotype, all patients had 
variants of aldosterone synthase.[16] In 2019, Spence hypothesised that 
Table 1. Physiologically individualised therapy based on renin/aldosterone profile
Primary aldosteronism
Liddle phenotype 
(due to variants of ENaC or  
genes affecting its function*) Renal/renovascular
Renin Low Low High
Aldosterone High Low High
Primary treatment Aldosterone antagonist 
(spironolactone or eplerenone)
Amiloride for men, where 
eplerenone is not available
(rarely surgery)
Amiloride Angiotensin receptor blocker or renin 
inhibitor (rarely revascularisation)
ENaC = renal tubular epithelial sodium channel.
*GRK, NEDD4L, CYP4A11, NPPA, UMOD, and perhaps others.
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some patients may have variants predisposing to both inappropriate 
aldosterone secretion and overactivity of the ENaC. For identification 
of physiologically appropriate therapy, it would be more practical to 
do phenotyping by measuring plasma renin and aldosterone than 
sequencing the beta chain of the ENaC and other genes that increase 
ENaC activity.
Case for amiloride in South Africa 
In SA, hypertension is one of the leading causes of death, and 
50% of treated hypertensive patients are not controlled.[17] In the 
USA, the Reasons for Geographic and Racial Differences in Stroke 
(REGARDS) study showed that African Americans are more likely 
to be diagnosed with hypertension, more likely to be treated, more 
likely to be treated intensively, and less likely to achieve BP control.[18] 
Although the reasons are complex, including poor adherence and 
lack of access to antihypertensive medication, it is now apparent 
that a large proportion of uncontrolled hypertension in blacks 
is due to polymorphisms in genes that increase ENaC function, 
resulting in salt and water retention, with suppressed renin and 
aldosterone. Amiloride is the specific treatment for uncontrolled 
hypertension. This has been demonstrated in an uncontrolled study 
in SA and more importantly in the randomised trial of physiological 
individualised treatment of resistant hypertension, as discussed 
above.[9,15] Triamterene also blocks the ENaC and is available in SA 
in combination with HCTZ 25 mg. It causes renal casts in more than 
half of the patients – thought to be due to interstitial nephritis – and 
is not recommended.[19]
Given that it is estimated that >5% of black hypertensives in SA 
have proven mutations of the ENaC and 10 - 20% have resistant 
hypertension due to the Liddle phenotype, it is simply not feasible to 
seek individual approval for the number of patients affected. Requests 
to register amiloride by the company that originally developed it, have 
not been successful, presumably because there would be no patent 
protection. Generic companies also cannot import amiloride unless it 
has been registered by the company that produced the original brand. 
Amiloride is registered in SA in the combination tablet 
Amiloride Co (HCTZ 50 mg/amiloride 5 mg), and approaches to 
a colleague linked to SAHPRA to use this as a basis for expedited 
registration were considered inappropriate. The combination tablet 
has too little amiloride and too much HCTZ to be clinically useful 
in adults with resistant hypertension. The studies demonstrating 
efficacy of amiloride used 10 mg daily; with the combination tablet, 
administration would result in 100 mg daily of HCTZ, with a high 
risk of depletion of sodium, potassium and magnesium.
Therefore, we have an important need for amiloride tablets without 
HTCZ to administer to black patients with severe and resistant 
hypertension. We are unable to provide these on a meaningful scale 
to benefit the patients. The regulations of SAPHRA prevent this, 
resulting in a classic Gordian knot that needs to be cut. The pen is 
said to be mightier than the sword, so unlike Alexander the Great, 
the knot can be cut with the stroke of a pen to modify Section 21 
regulations related to essential drugs not registered in SA. 
Conclusions
Amiloride is a WHO essential drug that has been registered in SA, 
but only in a combination product with too high a dose of HCTZ. 
Use of amiloride in black and mixed ancestry patients with severe 
and resistant hypertension is highly likely to improve BP control, with 
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